SAN FRANCISCO, July 28, 2023 (GLOBE NEWSWIRE) -- Augmedix (Nasdaq: AUGX), a healthcare technology company that delivers industry-leading, ambient medical documentation and data solutions to healthcare systems, physician practices, hospitals, and telemedicine practitioners, today announced it will report financial results for the second quarter ended June 30, 2023, on Monday, August 7, 2023, after the market closes. Company management will host a conference call that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Live audio of the conference call will be available on the “Events” section of the Company’s website at: https://ir.augmedix.com/news-events. Alternatively, interested parties can dial 877-407-3982 (toll-free) or 201-493-6780 (international) to listen. The webcast will be archived and available for replay after the event.
About Augmedix
Augmedix (Nasdaq: AUGX) delivers industry-leading, ambient medical documentation and data solutions to healthcare systems, physician practices, hospitals, and telemedicine practitioners. Augmedix is on a mission to help clinicians and patients form a human connection at the point of care with unobtrusive technology. Augmedix’s proprietary Notebuilder Platform extracts relevant data from natural clinician-patient conversations and converts that data into medical notes in real time, which are seamlessly transferred to the EHR. The company’s platform uses automatic speech recognition, natural language processing, including large language models, and medical documentation specialists to generate accurate and timely medical notes. Leveraging this platform, Augmedix’s products relieve clinicians of administrative burden, in turn, reducing burnout and increasing both clinician and patient satisfaction. Augmedix is also leading the revolution in transforming point-of-care information into valuable structured data that can drive lower revenue cycle management costs, higher reimbursement levels and deliver important clinical feedback to the point of care. Augmedix is headquartered in San Francisco, CA, with offices around the world. To learn more, visit www.augmedix.com.
Contact Information
Investors:
Matt Chesler, CFA
FNK IR
(646) 809-2183
This email address is being protected from spambots. You need JavaScript enabled to view it.
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media:
Kaila Grafeman
Augmedix
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$2.35 |
| Daily Volume: | 0 |
| Market Cap: | US$116.160M |
August 12, 2024 July 19, 2024 April 24, 2024 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
